Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
Anne-Laure Désage, Camille Léonce, Aurélie Swalduz, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

Oncogenic alterations in advanced NSCLC: a molecular super-highway
Alex Friedlaender, M. Pérol, Giuseppe Luigi Banna, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 36
KRAS in NSCLC: State of the Art and Future Perspectives
Priscilla Cascetta, Arianna Marinello, Chiara Lazzari, et al.
Cancers (2022) Vol. 14, Iss. 21, pp. 5430-5430
Open Access | Times Cited: 43
The strategic roles of four enzymes in the interconnection between metabolism and oncogene activation in non-small cell lung cancer: Therapeutic implications
Philippe Icard, Luca Simula, Ludovic Fournel, et al.
Drug Resistance Updates (2022) Vol. 63, pp. 100852-100852
Open Access | Times Cited: 39
Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas
Marina Salmón, Ruth Álvarez, Coral Fustero‐Torre, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 7
Open Access | Times Cited: 33
The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
Firas Batrash, Mahmoud Kutmah, Jun Zhang
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 22
Synthesis of Adagrasib (MRTX849), a Covalent KRASG12C Inhibitor Drug for the Treatment of Cancer
Cheng‐yi Chen, Zhichao Lu, Thomas Scattolin, et al.
Organic Letters (2023) Vol. 25, Iss. 6, pp. 944-949
Open Access | Times Cited: 18
A global analysis of the value of precision medicine in oncology – The case of non-small cell lung cancer
Thomas Hofmarcher, Chiara Malmberg, Peter Lindgren
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 14
Discovery of Potent SOS1 PROTACs with Effective Antitumor Activities against NCI-H358 Tumor Cells In Vitro/In Vivo
Xudong Pang, Dawei Cui, Binhua Lv, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 2, pp. 1563-1579
Closed Access | Times Cited: 5
Prospective virtual screening combined with bio-molecular simulation enabled identification of new inhibitors for the KRAS drug target
Amar Ajmal, Hind A. Alkhatabi, Roaa M. Alreemi, et al.
BMC Chemistry (2024) Vol. 18, Iss. 1
Open Access | Times Cited: 5
Deletion of the Long Non-coding RNA <i>ANRIL</i> In Addition to the Protein-Coding Genes of the INK4-ARF Locus in the A549 Cell Line: An Existing Phenomenon or a Novel Genetic Alteration?
Erfan Sherifi, Fardin Fathi, Mohammad Bagher Khadem Erfan, et al.
International Journal of Cancer Management (2025) Vol. 17, Iss. 1
Open Access
Synthetic Lethality of SHP2 and XIAP Suppresses Proliferation and Metastasis in KRAS‐mutant Nonsmall Cell Lung Cancer
Naijie Fu, Yuwen Sheng, Zhe Fan, et al.
Advanced Science (2025)
Open Access
Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
Man Wang, Lijie Zhu, Xiaoxu Yang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 12
Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies
Sajid Khan, Vivekananda Budamagunta, Daohong Zhou
Advances in cancer research (2023), pp. 145-184
Closed Access | Times Cited: 11
Reverse vaccinology and immunoinformatics approaches to design multi-epitope based vaccine against oncogenic KRAS
Prasanna Srinivasan Ramalingam, Sivakumar Arumugam
Medical Oncology (2023) Vol. 40, Iss. 10
Open Access | Times Cited: 11
Intracellular Delivery of Anti-Kirsten Rat Sarcoma Antibodies Mediated by Polymeric Micelles Exerts Strong In Vitro and In Vivo Anti-Tumorigenic Activity in Kirsten Rat Sarcoma-Mutated Cancers
Diana Rafael, Sara Montero‐Herradón, Pilar Carcavilla, et al.
ACS Applied Materials & Interfaces (2023) Vol. 15, Iss. 8, pp. 10398-10413
Closed Access | Times Cited: 9
Prediction of KRASG12C inhibitors using conjoint fingerprint and machine learning-based QSAR models
Tarapong Srisongkram, Patcharapa Khamtang, Natthida Weerapreeyakul
Journal of Molecular Graphics and Modelling (2023) Vol. 122, pp. 108466-108466
Closed Access | Times Cited: 9
Precision nanomedicine to treat non-small cell lung cancer
Akanksha Dessai, Usha Y. Nayak, Yogendra Nayak
Life Sciences (2024) Vol. 346, pp. 122614-122614
Open Access | Times Cited: 3
Design and development of dual targeting CAR protein for the development of CAR T-cell therapy against KRAS mutated pancreatic ductal adenocarcinoma using computational approaches
Prasanna Srinivasan Ramalingam, T. Premkumar, Vino Sundararajan, et al.
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Advances in Targeted Therapy Against Driver Mutations and Epigenetic Alterations in Non-Small Cell Lung Cancer
Jiajian Shi, Yuchen Chen, Chentai Peng, et al.
ONCOLOGIE (2022) Vol. 24, Iss. 4, pp. 613-648
Open Access | Times Cited: 14
Nanoformulation of the K-Ras(G12D)-inhibitory peptide KS-58 suppresses colorectal and pancreatic cancer-derived tumors
Kotaro Sakamoto, Yun Qi, Eijiro Miyako
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 8
A Novel TP53 Gene Mutation Sustains Non-Small Cell Lung Cancer through Mitophagy
Yuanli Wang, Kah Yong Goh, Zhencheng Chen, et al.
Cells (2022) Vol. 11, Iss. 22, pp. 3587-3587
Open Access | Times Cited: 13
Potential biomarkers uncovered by bioinformatics analysis in sotorasib resistant-pancreatic ductal adenocarcinoma
Prasanna Srinivasan Ramalingam, A. Priyadharshini, Isaac Arnold Emerson, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 7
Assessment of KRASG12C inhibitors for colorectal cancer
Gary A. Piazza, Preethi Chandrasekaran, Yulia Maxuitenko, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
Liquid Biopsy and Immuno-Oncology for Advanced Nonsmall Cell Lung Cancer
Léa Sinoquet, William Jacot, Xavier Quantin, et al.
Clinical Chemistry (2022) Vol. 69, Iss. 1, pp. 23-40
Closed Access | Times Cited: 12
Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun
Maristella Bungaro, Silvia Novello, Francesco Passiglia
Current Treatment Options in Oncology (2022) Vol. 23, Iss. 12, pp. 1699-1720
Closed Access | Times Cited: 11
Page 1 - Next Page

Scroll to top